There is currently no disease-modifying treatment available to halt or delay the progression of the disease pathology in dementia. An agreed core set of the best-available and most appropriate outcomes for disease modification would facilitate the design of trials and ensure consistency across disease modification trials, as well as making results comparable and meta-analysable in future trials.
To agree a set of core outcomes for disease modificat...
- Publication status:
- Peer review status:
- Peer reviewed
- Publisher's version
- NIHR Journals Library Publisher's website
- Health Technology Assessment Journal website
- Publication date:
- Acceptance date:
- Pubs id:
- Local pid:
- Paper number:
- Copyright holder:
- Queen’s Printer and Controller of HMSO
- Copyright date:
- Crown Copyright. © Queen’s Printer and Controller of HMSO 2017. This work was produced by Webster et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising.